Tel: 01789 267520

AVXS-101 (AveXis) Updates

AVXS-101 uses harmless, genetically-engineered viruses to increase SMN protein levels. It has recently received “Breakthrough Therapy” status. AveXis, the pharmaceutical company developing AVXS-101, has released results from the completed Phase I trial of the gene therapy drug.

Clinical Trials Now
 

Drug Development Updates:

2018

Novartis Agrees $8.7 Billion Deal to Acquire AveXis

AveXis Announce Additional Trials of AVXS-101 for SMA
 

2017

AveXis Announce Phase 1 Trial of AVXS-101 for SMA Type 2

Summary and comparison of results to date for nusinersen and gene therapy (Avexis-101)

AveXis to Imminently Initiate AVXS-101 Pivotal Trial in the US

AVXS-101 gene therapy manufacturing process streamlined

AveXis announce results from AVXS-101 Phase I trial

NEW EUROPEAN PIVOTAL STUDY ANNOUNCED BY AVEXIS
 

2016

NEW PIVOTAL STUDY ANNOUNCED BY AVEXIS

AVEXIS PROVIDES UPDATE ON ONGOING AVXS-101 TRIAL

AVXS-101 RECEIVES “BREAKTHROUGH THERAPY DESIGNATION”

AVEXIS PROVIDES UPDATE ON VIRAL GENE THERAPY TRIAL

AVEXIS COMPLETES PHASE I TRIAL PATIENT ENROLMENT

 

2014

AVEXIS GENE THERAPY GAINS ORPHAN DRUG STATUS   

REGENX REACH DEAL WITH AVEXIS TO ADVANCE POTENTIAL SMA GENE THERAPIES

SMN1 GENE THERAPY TRIAL INITIATED IN THE US

 

2013

SMN1 GENE THERAPY KNOWN AS SCAAV9.CB.SMN RECEIVES FAST TRACK STATUS IN THE US